News
End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...
Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<
